The safety profile of SGLT2 inhibitors appears robust, with no statistically significant differences noted between the SGLT2 inhibitor and control groups concerning AKI, hypoglycemia, UTIs, or hypotension. The gene discussed is SLC5A2; the disease is Hypoglycemia.